Return to Clinical Trials Search Results

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Primary Objectives 1. Examine the impact of SIGNATERATM on adjuvant treatment decisions 2. Determine the rate of patient s diagnosed with CRC recurrence while asymptomatic using SIGNATERA Secondary Objectives 1. Molecular residual disease clearance 2. Percent of patients undergoing surgery for oligometastatic recurrence 3. Survival in patients treated with adjuvant versus no adjuvant chemotherapy in patients with SIGNATERATM negative test results after surgery (first timepoint) 4. Overall survival 5. Impact of SIGNATERATM test results on patient quality of life

Primary Objectives 1. Examine the impact of SIGNATERATM on adjuvant treatment decisions 2. Determine the rate of patient s diagnosed with CRC recurrence while asymptomatic using SIGNATERA Secondary Objectives 1. Molecular residual disease clearance 2. Percent of patients undergoing surgery for oligometastatic recurrence 3. Survival in patients treated with adjuvant versus no adjuvant chemotherapy in patients with SIGNATERATM negative test results after surgery (first timepoint) 4. Overall survival 5. Impact of SIGNATERATM test results on patient quality of life